Results 251 to 260 of about 17,217,890 (291)

Management of non–clear cell renal cell carcinoma: Current approaches

Urologic Oncology: Seminars and Original Investigations, 2017
Non-clear cell renal cell carcinoma includes several histological variants. Tumor biology has significant effect on the duration of the disease. Prognosis at formally similar disease stages may differ despite same surgical treatment approaches to clear and non-clear cell renal cell carcinomas.
openaire   +2 more sources

Treatment for Non-clear Cell Renal Cell Carcinoma

2017
Non-clear cell (NCC) renal cell carcinoma (RCC) is less common and accounts for 25 % of all patients with metastatic RCC. Metastatic NCCRCC and clear cell (CC) RCC both respond infrequently to cytotoxic and cytokine therapy; however, compared with CCRCC patients, NCCRCC patients have a poorer prognosis.
openaire   +1 more source

An update on the treatment paradigm for non-clear cell renal cell carcinoma

Expert Review of Clinical Pharmacology
Non - clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of rare malignancies, representing approximately 20-25% of all renal cancers. Unlike clear cell RCC (ccRCC), these subtypes - papillary, chromophobe, collecting duct, translocation, molecularly defined variants and others - display distinct biological behaviors, genetic ...
Alessandro Rametta, Noemi Crippa, Simone Rota, Eleonora Gusmaroli, Marco Stellato, Elena Verzoni, Amedeo Nuzzo, Melanie Claps, Valentina Guadalupi, Giuseppe Procopio   +9 more
openaire   +2 more sources

Metastatic non‐clear cell renal cell carcinoma: current therapeutic options

BJU International, 2008
Non‐clear cell (ncc) renal cell carcinoma (RCC) accounts for ≈25% of all patients with metastatic RCC. It is refractory to standard immuno(chemo)therapy and, to date, no specific trials have been reported to evaluate the efficacy of novel targeted drugs in the different subtypes of metastatic nccRCC.
Andres J, Schrader, Peter J, Olbert, Axel, Hegele, Zoltan, Varga, Rainer, Hofmann   +4 more
openaire   +2 more sources

The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review

Clinical Genitourinary Cancer, 2019
Pazopanib is a protein tyrosine kinase inhibitor that limits tumor growth through angiogenesis inhibition. The use of other protein tyrosine kinase inhibitors, specifically sunitinib, within non-clear cell renal cell carcinoma (nccRCC) has led to increased survival with a decreased adverse event profile. The data for the treatment of nccRCC is limited,
Gregory T, Sneed, Sukdong, Lee, Jamie N, Brown, Julia M, Hammond   +3 more
openaire   +2 more sources

Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non–Clear Cell Renal Cell Carcinoma

European Urology, 2010
A 35-year-old woman presented with a 12-cm right renal mass with retroperitoneal lymph node involvement and pulmonary and bone metastases. Renal mass biopsy revealed an unclassified high-grade non-clear cell renal cell carcinoma (RCC) with eosinophilic cells. Due to the extent of the disease, neoadjuvant temsirolimus was initiated.
Faba, OR, Breda, A, Rosales, A, Palou, J, Algaba, F, Rey, PM, Villavicencio, H   +6 more
openaire   +3 more sources

Molecular and therapeutic landscape of non-clear cell renal carcinoma

Nature Reviews Urology
Non-clear cell renal cell carcinomas (nccRCC) include diverse subtypes such as papillary, oncocytic and chromophobe, collecting duct, molecularly defined and other rare histological subtypes, each associated with unique clinical, pathological, genetic and molecular features as well as therapeutic challenges.
Prerna R. Nepali, Ahmed Eraky, Kennedy E. Okhawere, Navneet Dogra, Reza Mehrazin, Ketan Badani, Natasha Kyprianou   +6 more
openaire   +2 more sources

Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib

Clinical Genitourinary Cancer, 2017
Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited.We conducted a retrospective data analysis of records of consecutive metastatic non-clear ...
Matrana, Marc R., Baiomy, Ali, Campbell, Matthew, Alamri, Suhail, Shetty, Aditya, Teegavarapu, Purnima, Kalra, Sarathi, Xiao, Lianchun, Atkinson, Bradley, Corn, Paul, Jonasch, Eric, Elsayes, Khaled M., Tannir, Nizar M.   +12 more
openaire   +5 more sources

PD-L1 expression in non-clear cell renal cell carcinoma.

Journal of Clinical Oncology, 2014
424 Background: Programmed death-1 (PD-1) receptor negatively regulates T cell-mediated responses.PD-1 ligand (PD-L1) is aberrantly expressed in clear cell renal cell carcinoma (ccRCC) and is associated with worse prognosis. Levels of PD-L1 expressions in non-ccRCC and its association with clinicopathological features and survival are unknown ...
André P Fay, Marcella Callea, Kathryn P. Gray, Thai Huu Ho, Jiaxi Song, Ingrid Carvo, Megan E. Lampron, Melissa L. Stanton, David F. McDermott, Michael B. Atkins, Gordon J Freeman, Michelle S. Hirsch, Sabina Signoretti, Toni K. Choueiri   +13 more
openaire   +1 more source

Systemic therapy for non–clear cell renal cell carcinomas: A systematic review

Journal of Oncology Pharmacy Practice
Objective Renal cell carcinoma (RCC) is the most common kidney cancer, with clear cell RCC being the predominant subtype. However, non-clear cell RCC constitutes a significant proportion of cases, presenting distinct challenges in treatment due to its varied histological subtypes.
Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran   +7 more
openaire   +2 more sources